Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.
Polychemotherapy including idarubicin was administered during the second trimester to treat acute lymphoblastic leukemia. The infant delivered at 28 weeks' gestation had acute cardiac failure attributed to the cardiotoxic effect of idarubicin. Cardiotoxicity may be caused by idarubicin's biophysical properties that facilitate its transplacental passage. Idarubicin should be used with extreme caution during pregnancy.
Achtari
C
C
Service de Gynécologie et Obstetrique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Hohlfeld
P
P
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics* / Q000506:poisoning*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D015255:Idarubicin / Q000493:pharmacokinetics* / Q000506:poisoning*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000378:metabolism*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin